Clinical trials: Second Line Treatment
Cholangiocarcinoma
RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy
The purpose of this study is to see if the investigational drug, RRx-001, an epigenetic agent, which turns on a number of beneficial genes that the tumor has silenced, can resensitize the tumor(s), in other words make it/them…
- Trial name
- EPIC (NCT02452970)
- Testing
- RRx-001, Gemcitabine and cisplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- EpicentRx, Inc.
Breast Cancer
MEtronomic TrEatment Option in Advanced bReast cAncer
This is a multi-center, randomized phase II trial that will randomise women with ER-positive, HER2-negative (Human Epidermal Growth factor Receptor 2-negative) metastatic or locally relapsed breast cancer in a ratio of 1:1 to…
- Trial name
- METEORA-II (NCT02954055)
- Testing
- Paclitaxel, Cyclophosphamide, Capecitabine
- Where
- 20 sites in Italy
- Volunteers
- 140 people
- Sponsor
- ETOP IBCSG Partners Foundation
Bladder Cancer
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
The primary objective of this study is to determine in subjects with metastatic measurable bladder cancer (or urothelial cancers originating elsewhere in the genitourinary tract) who have progressed on 1 prior chemotherapeutic…
- Trial name
- NCT01331824
- Testing
- Amrubicin
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Matthew Galsky
Non-Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP).
- Trial name
- NCT00336583
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Asan Medical Center
Breast Cancer, Metastatic Breast Cancer
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
This phase 2 clinical trial will evaluate the efficacy of the combination of pemetrexed and sorafenib in patients with recurrent or metastatic Triple Negative Breast Cancer (TNBC).
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT02624700
- Testing
- Experimental Arm A: Pemetrexed, Experimental Arm A: Sorafenib, Experimental Arm B: Pemetrexed
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Virginia Commonwealth University
Endometrial Cancer
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or…
- Trial name
- IXAMPLE2 (NCT00883116)
- Testing
- Ixabepilone, Doxorubicin, Paclitaxel
- Where
- 93 sites in United States, Argentina and 17 more
- Volunteers
- 551 people
- Sponsor
- R-Pharm
HIV Infections
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
The investigators hypothesize that following virological failure of a standard NNRTI+2N(T)RTI regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and 2N(T)RTIs will offer comparable efficacy to…
- Trial name
- SECOND-LINE (NCT00931463)
- Testing
- raltegravir, 2N(t)RTI, Ritonavir-boosted lopinavir
- Where
- 44 sites in Argentina, Australia and 15 more
- Volunteers
- 558 people
- Sponsor
- Kirby Institute
Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
Drugs used in chemotherapy, such as rebeccamycin analog, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
- Trial name
- NCT00084487
- Testing
- becatecarin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers
This is a Phase IIa, open-label, single-arm, multi-center study to evaluate the efficacy and safety of orally administered MEK inhibitor trametinib as the second line in subjects with advanced or metastatic biliary tract cancers…
- Trial name
- NCT01943864
- Testing
- Trametinib (single tablet), Trametinib (Multiple tablet)
- Where
- 5 sites in Japan
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Triple-negative Breast Cancer
A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
The main purpose of this study was to assess the antitumor activity of three combinations: i) LAG525 + spartalizumab; ii) LAG525 + spartalizumab + carboplatin, and iii) LAG525 + carboplatin in participants with advanced…
- Trial name
- NCT03499899
- Testing
- LAG525, PDR001, Carboplatin
- Where
- 33 sites in United States, Argentina and 15 more
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer
Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment
the primary objective is to characterise the impact of gefitinib on the Response Evaluation Criteria in Solid Tumours (RECIST) based assessments; objective response rate (ORR ; confirmed complete response(CR) or partial response…
- Trial name
- ICARUS (NCT01530334)
- Testing
- Gefitinib 250mg
- Where
- 24 sites in Italy
- Volunteers
- 61 people
- Sponsor
- AstraZeneca
Recurrent Bladder Cancer, Stage III Bladder Cancer
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery.
- Conditions
- Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT01382706
- Testing
- docetaxel, lapatinib ditosylate, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Neoplasms, Breast
Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects
This is an open-label, single-arm, multi-center, Phase II study to determine the activity of vinorelbine plus lapatinib in either first- or second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC).
- Trial name
- NCT00709618
- Testing
- Lapatinib, Vinorelbine
- Where
- 22 sites in United States
- Volunteers
- 44 people
- Sponsor
- GlaxoSmithKline
Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.
- Trial name
- NCT02898077
- Testing
- Ramucirumab, Paclitaxel
- Where
- 32 sites in China, Malaysia and 2 more
- Volunteers
- 440 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Adenocarcinoma
Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
This phase II trial studies how well regorafenib and gemcitabine hydrochloride work as second-line therapy (treatment given when initial treatment doesn't work) in treating patients with pancreatic cancer that has spread to other…
- Trial name
- NCT02383433
- Testing
- Regorafenib, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center